Hormonal suppression effectively manages endometriosis symptoms and chronic pain. However, many clinicians express concern regarding endometriosis treatment bone health outcomes. Consequently, a recent systematic review published in Obstetrics & Gynecology evaluates how medical therapies influence bone mineral density (BMD).

Specifically, researchers analyzed 37 clinical studies after screening over 1,000 papers. Furthermore, the pooled results showed that GnRH agonists significantly reduced BMD after 12 months of use. In addition, both leuprolide and goserelin treatments led to a notable decrease in bone mass. Although add-back therapy helps, BMD nevertheless declined in most patients because of severe estrogen suppression. Similarly, dienogest also impacted bone health. For example, it was associated with lower BMD at both 6 and 12 months. Consequently, doctors should monitor these patients closely during treatment. Moreover, GnRH antagonists showed a significant decrease, particularly without add-back protocols. Therefore, clinicians must assess bone risks before starting long-term therapy.

Monitoring Endometriosis Treatment Bone Health

Additionally, Indian guidelines from the Indian Fertility Society recommend limiting GnRH analogs since they cause significant bone loss. Furthermore, the ICMR "EndoCare India" model supports standardized care and regular screening. Thus, these proactive steps help ensure that bone preservation remains a clinical priority. Consequently, doctors must balance effective pain relief with the risk of future fractures. Moreover, regular BMD screening and nutritional support are essential for high-risk individuals. In summary, expert consensus is needed for better long-term bone management.

Frequently Asked Questions

Which hormonal therapy causes the most significant bone loss?

Based on the meta-analysis, GnRH antagonists without add-back therapy showed the largest BMD decrease at six months. Although GnRH agonists and dienogest also cause loss, the lack of add-back therapy significantly worsens the impact on bone mineral density.

Is add-back therapy effective for bone preservation?

Yes, add-back therapy is highly effective because it provides a low level of estrogen to protect the bones. However, it does not completely eliminate bone loss. Therefore, clinicians should still perform regular monitoring during extended treatment cycles.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Desilets J et al. Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026 Mar 19. doi: 10.1097/AOG.0000000000006241. PMID: 41855532.


2. Indian Fertility Society (IFS). Consensus Statement on the Medical Management of Endometriosis.


3. Indian Council of Medical Research (ICMR). EndoCare India: Multidisciplinary Care Guidelines for Endometriosis.